Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited (GLENMARK.NS) Stock Overview
Explore Glenmark Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
588.4B
P/E Ratio
55.24
EPS (TTM)
$37.67
ROE
0.12%
GLENMARK.NS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Glenmark Pharmaceuticals Limited (GLENMARK.NS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 61.78, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2114.31.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 55.24 and a market capitalization of 588.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.